Article Text

Download PDFPDF

675 TACTI-003: A randomized phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma
  1. Irene Brana1,
  2. Valerii Cheshuk2,
  3. Claus Andrup Kristensen3,
  4. Maria Eugenia Ortega4,
  5. Brieuc Sautois5,
  6. Antonio López-Pousa6,
  7. Judith Christian7,
  8. Willem Lybaert8,
  9. Julio Peguero9,
  10. John Park10,
  11. Robert Metcalf11,
  12. Lisle Nabell12,
  13. Bernard Doger de Spéville13,
  14. Jordi Rubió Casadevall14,
  15. Ainara Soria Rivas15,
  16. Martin Forster16 and
  17. Frederic Triebel17
  1. 1Vall d’Hebron Institute of Oncology, Barcelona, Spain
  2. 2ARENSIA Exploratory Medicine LLC, Kyiv, Ukraine
  3. 3Rigshospitalet, Copenhagen, Denmark
  4. 4Hospital Universitario Miguel Servet, Zaragoza, Spain
  5. 5Centre Hospitalier Universitaire (CHU), Liège, Belgium
  6. 6Hospital de la Santa Creu i de Sant Pau, Barcelona, Spain
  7. 7Nottingham University Hospitals, NHS, Nottingham, UK
  8. 8VITAZ, Sint-Niklaas, Belgium
  9. 9Oncology Consultants, P.A, Houston, TX, USA
  10. 10Macquarie University Hospital, NSW 2109, Australia
  11. 11The Christie NHS Foundation Trust, Manchester, UK
  12. 12University of Alabama at Birmingham UAB, Birmingham, AL, USA
  13. 13START Madrid, Madrid, Spain
  14. 14Institut Català d’Oncologia – Hospital, Girona, Spain
  15. 15Hospital Universitario Ramón y Cajal, Madrid, Spain
  16. 16UCL Cancer Institute; University College London Hospitals NHS Foundation – The Harley Street Clinic, London, UK
  17. 17Immutep S.A.S., Chatenay Malabry, France


Background Eftilagimod alpha (efti) is a soluble LAG-3 protein targeting a subset of MHC class II molecules that mediate antigen-presenting cell (APC) and then CD8 T-cell activation. Data from a non-randomized, phase II trial of efti plus pembrolizumab (TACTI-002) showed encouraging antitumor activity and manageable safety when given as second-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC). TACTI-003 (NCT04811027) is a multicenter, open-label, randomized phase IIb trial to investigate efti plus pembrolizumab in the first line setting for RM-HNSCC.

Methods A total of 154 patients (pts) are currently being recruited into two cohorts (A+B). In cohort A, pts with tumors that are CPS≥1 will be randomly assigned 1:1 to receive either efti (30 mg subcutaneously Q2W for initial 6 months, thereafter Q3W) plus pembrolizumab (400 mg intravenously Q6W) for up to two years or pembrolizumab alone. Randomization will be stratified by CPS (1-19 vs. ≥ 20) and ECOG PS (0 vs. 1). Pts with tumors that are CPS<1 will receive efti plus pembrolizumab (cohort B). Imaging will be performed every 9 weeks. The primary endpoint (EP) is the objective response rate (ORR) by RECIST1.1. Secondary EPs include overall survival, ORR according to iRECIST, time to and duration of response, disease control rate, progression-free survival, the occurrence of anti-efti -specific antibodies, safety, and quality of life. Exploratory endpoints comprise biomarkers.

Acknowledgements · We thank all the participating patients & their families.

· We thank the dedicated clinical trial investigators & their team members.

· Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA provided pembrolizumab for the study.

· Sponsored by Immutep.

Trial Registration The trial identifiers are IMP321-P022 (Sponsor code), Keynote-PNC-34 (MSD code), 2021-000055-39 (EudraCT) and NCT04811027 (

Ethics Approval This has been approved by relevant Competent Authorities, Ethics Committees, and Institutional Review Boards.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.